Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, placebo-controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of YTX-7739, a novel oral inhibitor of Stearoyl-CoA-desaturases, in healthy volunteers and patients with Parkinson's disease

X
Trial Profile

Randomized, double-blind, placebo-controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of YTX-7739, a novel oral inhibitor of Stearoyl-CoA-desaturases, in healthy volunteers and patients with Parkinson's disease

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YTX 7739 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CHDR1916/7739-01-002
  • Sponsors Yumanity Therapeutics
  • Most Recent Events

    • 19 Jan 2022 According to a Yumanity Therapeutics media release, in response to IND application submitted in December 2021, the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on multidose clinical trials of YTX-7739. The FDA has not halted single dose clinical trials. The partial clinical hold suspends initiation of multiple dose clinical trials in the U.S. until the FDA's questions have been addressed.
    • 19 Jan 2022 Status changed from recruiting to suspended, according to Yumanity Therapeutics Media Release.
    • 10 Nov 2021 According to Yumanity Therapeutics Media Release, the full data set from this study will be presented at an upcoming medical conference; Management will host a conference call to discuss the results of the Phase 1b clinical trial at 8:30 a.m. EST, Wednesday, November 10.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top